Latest Financial Health News

Aerometrex Limited has reported record first half revenue and EBITDA for the six months ending December 2025, driven by strong MetroMap subscription growth and a rebound in LiDAR sales.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Titan Minerals secures a strategic $10 million investment from Lingbao Gold International, advancing its Dynasty Gold and Linderos Copper projects with promising drilling results and a strong cash position.

Nickel Industries reported a 57% drop in quarterly EBITDA due to mining quota delays but showcased robust HPAL margins and advanced commissioning at its Excelsior project, supported by a strategic investment from Sphere Corp.

Appen Limited delivered a robust Q4 FY25, driven by explosive growth in its China segment and strong gains in generative AI projects globally, boosting revenue and profitability significantly.

Horizon Oil reported an 18% rise in production and sales volumes in Q2 FY26, driven by its first full quarter of Thailand asset output. The company also maintained strong cashflow, paid a final FY25 dividend, and secured a long-term gas supply agreement in Australia’s Northern Territory.

D3 Energy has reported encouraging progress in its South African helium and methane operations, highlighted by improved gas flow rates from the Nooitgedacht Major well and an upgraded US OTCQX listing to broaden investor reach.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

Perpetual Limited’s second quarter FY26 update reveals a mixed performance with strong Corporate Trust growth balancing net outflows in Asset Management, while Wealth Management remains stable amid ongoing sale talks.

Lark Distilling Co. has reported its sixth consecutive quarter of sales growth, with net sales rising 11% to $5 million in Q2 FY26, as it prepares to launch a refreshed brand portfolio domestically and internationally.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.